Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Genentech, Inc.
Age
18–55
Sex
ALL
Healthy volunteers
Accepted
You may be eligible if
Female volunteers will be non-pregnant, non-lactating, and either postmenopausal for at least 1 year or surgically sterile
Male volunteers will either be sterile, or agree to use adequate methods of contraception
Body mass index (BMI) range 18 to 32 kg/m2, inclusive
No clinically significant findings from medical history, physical examination, 12-lead ECG, vital signs; and clinical laboratory evaluations
Negative hepatitis B virus, hepatitis C virus and negative HIV antibody screens
You may not be if
Significant history or clinical manifestation of any significant metabolic, allergic, dermatological, hepatic, renal, hematological, pulmonary, cardiovascular, gastrointestinal, neurological, or psychiatric disorder
History of significant hypersensitivity, intolerance, or allergy to any drug compound, food, or other substance
History of stomach or intestinal surgery or resection that would alter absorption and/or excretion of orally administered study drugs
History of alcoholism or drug addiction within 1 year prior to Check-in
History of chronic proton pump inhibitor (PPI) use within 6 months of Check-in, or use of PPIs, H2-receptor antagonists, or antacids within 1 month prior to Check-in and during the entire study
Clinically significant history of liver disease, including viral or other hepatitis, current alcohol abuse, or cirrhosis
History type 1 or 2 diabetes and/or elevated fasting glucose at baseline
Malabsorption syndrome or other condition that would interfere with enteral absorption
Use of any tobacco- or nicotine containing- products
Participation in any other investigational study drug or biologic agent trial in which receipt of an investigational study drug occurred within 5 half-lives or 30 days, whichever is longer to Check-in and during the entire study duration
Clareo Health | A Drug Interaction Study of GDC-0032 Co-administered With Rifampin or Itraconazole in Healthy Volunteers
